Helius Medical Tech reports $2.5 million Q2 revenue from staking
Helius Medical Tech said second-quarter revenue was $2.5 million, primarily from staking, and described a shift toward digital asset treasury, validator infrastructure and advisory services.
On Friday, Helius Medical Tech (NASDAQ: HSDT ) discussed second-quarter financial results during its earnings call.
The full transcript is provided below.
This content is powered APIs.
For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Helius Medical Tech reported $2.5 million in second-quarter revenue, primarily from staking, marking a significant increase from the previous year.
The company divested its cash-consuming medical device business, acquiring a profitable Hong Kong trust company to align with its new digital asset treasury and infrastructure focus.
Key strategic initiatives include launching a validator cluster in Tokyo and securing a third-party stake commitment of half a million SOL.
The company plans to expand its validator infrastructure and advisory services in the Asia-Pacific region, with an emphasis on institutional partnerships.
Management highlighted plans for ongoing share repurchases and capital allocation to maximize SOL per share, reflecting a focus on shareholder value.
Full Transcript OPERATOR Good afternoon, everyone, and thank you for participating in today's call to discuss Helius Medical Tech's operating results for the second quarter 2026, ended June 30, 2026.
The second quarter of 2026 earnings press release was issued today, August 14th, at approximately 4:25 p.m.
Eastern Time and is available on the Investor Relations section of Helius Medical Tech's website.
Joining us today are Joseph Chee, Chairman and Chief Executive Officer; Cosmo Jeong, Director of Helius Medical Tech and General Partner at Pantera Capital; and Madeline Gianni, Chief Financial Officer.
All participants are in a listen-only mode.
Following management's prepared remarks, we will open the call for questions.
To ask a question, please press star followed by 1, star 1-1, on your telephone.
Today's call is being recorded.
I would now like to turn the call over to Jake Practice with M Group Strategic Communications for introductory remarks.
Please go ahead, sir.
Jake Practice, M Group Strategic Communications Thank you, operator.
Before we begin, I'd like to inform you that comments and responses to questions during today's call reflect management's views as of today, August 14, 2026, only and include forward-looking statements and opinion statements, including predictions, estimates, policies, plans, expectations, and other similar information.
Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties.
These risks and uncertainties are more fully described in our press release issued today and in the sections entitled Risk Factors in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission, or the SEC, on June 30, 2026, as well as in subsequent filings with the SEC.
Our SEC filings can be found on our website or on the SEC's website.
Investors are cautioned not to place undue reliance on forward-looking statements.
We disclaim any obligation to update or revise these forward-looking statements.
Please note this conference call will be available for audio replay on our website under the News and Events section of our Investor Relations page.
With that, I would now like to turn the call over to Helius Medical Tech's Chairman and Chief Executive Officer, Joseph Chee.
Joseph Chee (Chairman and Chief Executive Officer) Good afternoon everyone and welcome to Solana Company's second quarter 2026 earnings call.
On our first quarter call I detailed our multifaceted digital asset Treasury, Platform and Flywheel strategy for the first time—Advisory, Validator Infrastructure, Staking and Treasury—each designed to strengthen the others and diversify Solana Company's revenue sources.
Today I'm pleased to report on the progress of this build-out.
Our first institutional validator cluster is operational in Tokyo.
We secured our first third-party stake commitment of around half a million SOL in July and expect to report the results in the third quarter of 2026.
We also addressed the legacy elements of the business by divesting the cash-consuming medical device business.
We swapped the legacy business unit out with the acquisition of a Hong Kong regulated trust company, a profitable enterprise that allows us to better realize the financial focus of our new operating model.
The assets in our treasury also continue to generate value.
Staking rewards contributed 2.5 million, or 31.2 thousand SOL, in the second quarter.